RAPT Therapeutics Announces Pricing of $75 Million Public Offering

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its underwritten public offering of 2,500,000 shares of common stock at a public offering price of $30.00 per share.

Click to view original post